Clinical trial
Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer
NCT00091858 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00091858 |
|---|---|
| Title | Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer |
| Official title | A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Anemia, Cancer |
| Intervention type | Drug |
| Interventions | Darbepoetin Alfa, Placebo |
| Enrollment | 1,000 |
| Start date | Apr 1, 2004 |
| Primary completion | Oct 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Sep 21, 2004 |
| Last update posted | May 8, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: